Jesse K McKenney
Overview
Explore the profile of Jesse K McKenney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
209
Citations
3757
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhattarai R, McKenney J, Alaghehbandan R, Liu X, Cox R, Myles J, et al.
Am J Surg Pathol
. 2025 Feb;
PMID: 39995242
Atypical intraductal proliferation (AIP) of the prostate is characterized by morphologic features exceeding that of high-grade prostatic intraepithelial neoplasia but not meeting strict diagnostic criteria for intraductal carcinoma. We examined...
2.
Sangoi A, Shahabi A, Hirsch M, Kao C, Deebajah M, Barletta J, et al.
Am J Clin Pathol
. 2024 Dec;
PMID: 39720998
Objectives: Urothelial carcinoma in situ (CIS) with early papillary formation is terminology sometimes used to suggest incipient high-grade papillary urothelial carcinoma (PUC) but may lead to confusion between true CIS...
3.
Nguyen J, Li J, Ding C, Weight C, McKenney J
Ann Diagn Pathol
. 2024 Dec;
75:152427.
PMID: 39644729
Prostatic adenocarcinomas with large cribriform glands/intraductal carcinoma (LC/IDC), or the recently proposed unfavorable histology, are associated with adverse outcomes after radical prostatectomy. However, Gleason pattern 4 carcinomas without LC/IDC (or...
4.
Sharma A, Khaitan N, Bhattarai R, Homsi H, McKenney J, Cheng Y
Int J Surg Pathol
. 2024 Nov;
:10668969241295687.
PMID: 39533816
This report delineates an intriguing example of advanced prostatic adenocarcinoma displaying distinctive histopathological characteristics associated with a fusion, a genomic anomaly predominantly identified in central nervous system tumors. A 66-year-old...
5.
Ding C, De Paula Oliveira L, Lotan T, Argani P, McKenney J, Epstein J
Am J Surg Pathol
. 2024 Jul;
48(9):1198-1200.
PMID: 38963190
No abstract available.
6.
Nguyen J, Harik L, Klein E, Li J, Corrigan D, Liu S, et al.
Histopathology
. 2024 Jun;
85(4):598-613.
PMID: 38828674
Aims: Histological grading of prostate cancer is a powerful prognostic tool, but current criteria for grade assignment are not fully optimised. Our goal was to develop and test a simplified...
7.
Newcomb L, Schenk J, Zheng Y, Liu M, Zhu K, Brooks J, et al.
JAMA
. 2024 May;
331(24):2084-2093.
PMID: 38814624
Importance: Outcomes from protocol-directed active surveillance for favorable-risk prostate cancers are needed to support decision-making. Objective: To characterize the long-term oncological outcomes of patients receiving active surveillance in a multicenter,...
8.
Lobo J, Canete-Portillo S, Pena M, McKenney J, Aron M, Massicano F, et al.
Mod Pathol
. 2024 Apr;
37(6):100492.
PMID: 38614322
Juxtaglomerular cell tumor (JGCT) is a rare neoplasm, part of the family of mesenchymal tumors of the kidney. Although the pathophysiological and clinical correlates of JGCT are well known, as...
9.
Ding C, Van Roo J, Kryvenko O, Ye H, McKenney J, Epstein J
Am J Surg Pathol
. 2024 Jan;
48(4):387-394.
PMID: 38270560
A well-differentiated papillary mesothelial tumor (WDPMT) and malignant mesothelioma are 2 well-recognized entities arising from the testis tunica vaginalis. Another mesothelial lesion exclusively seen at this site is mesothelioma of...
10.
Liu S, Hawley S, Kunder C, Hsu E, Shen M, Westphalen L, et al.
Sci Rep
. 2024 Jan;
14(1):486.
PMID: 38177207
Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences clinical decision-making between treatment and active surveillance. The development of novel predictive biomarkers will help...